Who are SonoVue®'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Perflutren lipid, Contrast-Enhanced Ultrasound using Lumason, Definity infusion, Optison echocardiography contrast agent, perflutren lipid microspheres, Sonovue and Sonazoid.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/sonovue.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-15 · How we verify

SonoVue® — Competitive Intelligence Brief

SonoVue® (SonoVue®) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Ultrasound contrast agent. Area: Imaging.

phase 3 Ultrasound contrast agent Imaging Small molecule Live · refreshed every 30 min

Target snapshot

SonoVue® (SonoVue®) — GE Healthcare. SonoVue is a microbubble ultrasound contrast agent that enhances ultrasound imaging.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class
SonoVue® TARGET	SonoVue®	GE Healthcare	phase 3	Ultrasound contrast agent
Perflutren lipid	Perflutren lipid	UNC Lineberger Comprehensive Cancer Center	marketed	Ultrasound contrast agent
Contrast-Enhanced Ultrasound using Lumason	Contrast-Enhanced Ultrasound using Lumason	Children's Hospital of Philadelphia	marketed	Ultrasound contrast agent
Definity infusion	Definity infusion	Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University	marketed	Ultrasound contrast agent
Optison echocardiography contrast agent	Optison echocardiography contrast agent	University of Utah	marketed	Ultrasound contrast agent
perflutren lipid microspheres	perflutren lipid microspheres	University of Virginia	phase 3	Ultrasound contrast agent
Sonovue and Sonazoid	Sonovue and Sonazoid	Second Affiliated Hospital, School of Medicine, Zhejiang University	phase 3	Ultrasound contrast agent

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Ultrasound contrast agent class)

Second Affiliated Hospital, School of Medicine, Zhejiang University · 2 drugs in this class
Bracco Diagnostics, Inc · 1 drug in this class
Centre Hospitalier Régional Metz-Thionville · 1 drug in this class
Children's Hospital of Philadelphia · 1 drug in this class
GE Healthcare · 1 drug in this class
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University · 1 drug in this class
Sunnybrook Health Sciences Centre · 1 drug in this class
UNC Lineberger Comprehensive Cancer Center · 1 drug in this class
University of Utah · 1 drug in this class
Acusphere · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). SonoVue® — Competitive Intelligence Brief. https://druglandscape.com/ci/sonovue. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab